Background: Diarrheal disease accounts for a large proportion of childhood deaths in North Korea, however, information regarding its management in North Korean clinical settings is limited. The absence of a reliable diarrheal disease database hinders efforts to determine priorities for support. Methods: Articles published in three major North Korean medical journals between 2012 and 2019 were analyzed to determine the clinical aspects of diagnosing and treating diarrhea. A total of 43 articles were identified during the screening process. Original articles and case reports focusing on the clinical features of diarrheal disease in the pediatric population were included. Results: The clinical features and markers of several types of diarrheal diseases, including infectious diarrhea (20.9%) and diarrhea due to indigestion or malabsorption (18.6%), were assessed. Healthcare providers used multiple treatment modalities, including rehydration solutions, antibiotics, probiotics, and vitamin supplementation. Therapeutic trials on North Korean Oriental medicine were also conducted in more than half of the studies (55.8%). Conclusion This review provides insights into understanding the types of diarrhea and unmet needs in clinical settings in North Korea. Follow-up studies are required to interpret the situation in detail.

Background: Diarrheal disease accounts for a large proportion of childhood deaths in North Korea, however, information regarding its management in North Korean clinical settings is limited. The absence of a reliable diarrheal disease database hinders efforts to determine priorities for support. Methods: Articles published in three major North Korean medical journals between 2012 and 2019 were analyzed to determine the clinical aspects of diagnosing and treating diarrhea. A total of 43 articles were identified during the screening process. Original articles and case reports focusing on the clinical features of diarrheal disease in the pediatric population were included. Results: The clinical features and markers of several types of diarrheal diseases, including infectious diarrhea (20.9%) and diarrhea due to indigestion or malabsorption (18.6%), were assessed. Healthcare providers used multiple treatment modalities, including rehydration solutions, antibiotics, probiotics, and vitamin supplementation. Therapeutic trials on North Korean Oriental medicine were also conducted in more than half of the studies (55.8%). Conclusion This review provides insights into understanding the types of diarrhea and unmet needs in clinical settings in North Korea. Follow-up studies are required to interpret the situation in detail.

Background: Diarrheal disease accounts for a large proportion of childhood deaths in North Korea, however, information regarding its management in North Korean clinical settings is limited. The absence of a reliable diarrheal disease database hinders efforts to determine priorities for support. Methods: Articles published in three major North Korean medical journals between 2012 and 2019 were analyzed to determine the clinical aspects of diagnosing and treating diarrhea. A total of 43 articles were identified during the screening process. Original articles and case reports focusing on the clinical features of diarrheal disease in the pediatric population were included. Results: The clinical features and markers of several types of diarrheal diseases, including infectious diarrhea (20.9%) and diarrhea due to indigestion or malabsorption (18.6%), were assessed. Healthcare providers used multiple treatment modalities, including rehydration solutions, antibiotics, probiotics, and vitamin supplementation. Therapeutic trials on North Korean Oriental medicine were also conducted in more than half of the studies (55.8%). Conclusion This review provides insights into understanding the types of diarrhea and unmet needs in clinical settings in North Korea. Follow-up studies are required to interpret the situation in detail.

Background: Diarrheal disease accounts for a large proportion of childhood deaths in North Korea, however, information regarding its management in North Korean clinical settings is limited. The absence of a reliable diarrheal disease database hinders efforts to determine priorities for support. Methods: Articles published in three major North Korean medical journals between 2012 and 2019 were analyzed to determine the clinical aspects of diagnosing and treating diarrhea. A total of 43 articles were identified during the screening process. Original articles and case reports focusing on the clinical features of diarrheal disease in the pediatric population were included. Results: The clinical features and markers of several types of diarrheal diseases, including infectious diarrhea (20.9%) and diarrhea due to indigestion or malabsorption (18.6%), were assessed. Healthcare providers used multiple treatment modalities, including rehydration solutions, antibiotics, probiotics, and vitamin supplementation. Therapeutic trials on North Korean Oriental medicine were also conducted in more than half of the studies (55.8%). Conclusion This review provides insights into understanding the types of diarrhea and unmet needs in clinical settings in North Korea. Follow-up studies are required to interpret the situation in detail.

Allogeneic stem cell transplantation (allo-SCT) is a salvage treatment option for patients with relapsed or refractory lymphoid malignancies. However, the clinical variables impacting outcomes in these patients remain unclear. We analyzed 58 patients who underwent allo-SCT for lymphoid malignancies, including B-cell lymphoma (BCL, n = 20), Hodgkin’s disease (n = 3), multiple myeloma (n = 9), natural killer/T-cell lymphoma (NK/TCL, n = 4), and TCL (n = 22).The median progression-free survival (PFS) was 27.4 months, while the median overall survival (OS) was 30.6 months.In univariate analysis, human leukocyte antigen (HLA) matching and complete remission status post-transplantation were associated with improved PFS and OS. However, only post-transplant response remained significant for both sur‑ vival outcomes in the multivariate analysis. Moreover, HLA matching was associated with a significantly improved PFS in patients with BCL and NK/TCL, but with better OS only in those with BCL. Complete remission after transplantation was associated with better PFS and OS in patients with BCL, NK/TCL, and TCL. Our results indicate that post-transplant response is an important prognostic indicator in allo-SCT for lymphoid malignancies and may guide clinical decisions and additional treatment.

Allogeneic stem cell transplantation (allo-SCT) is a salvage treatment option for patients with relapsed or refractory lymphoid malignancies. However, the clinical variables impacting outcomes in these patients remain unclear. We analyzed 58 patients who underwent allo-SCT for lymphoid malignancies, including B-cell lymphoma (BCL, n = 20), Hodgkin’s disease (n = 3), multiple myeloma (n = 9), natural killer/T-cell lymphoma (NK/TCL, n = 4), and TCL (n = 22).The median progression-free survival (PFS) was 27.4 months, while the median overall survival (OS) was 30.6 months.In univariate analysis, human leukocyte antigen (HLA) matching and complete remission status post-transplantation were associated with improved PFS and OS. However, only post-transplant response remained significant for both sur‑ vival outcomes in the multivariate analysis. Moreover, HLA matching was associated with a significantly improved PFS in patients with BCL and NK/TCL, but with better OS only in those with BCL. Complete remission after transplantation was associated with better PFS and OS in patients with BCL, NK/TCL, and TCL. Our results indicate that post-transplant response is an important prognostic indicator in allo-SCT for lymphoid malignancies and may guide clinical decisions and additional treatment.

Allogeneic stem cell transplantation (allo-SCT) is a salvage treatment option for patients with relapsed or refractory lymphoid malignancies. However, the clinical variables impacting outcomes in these patients remain unclear. We analyzed 58 patients who underwent allo-SCT for lymphoid malignancies, including B-cell lymphoma (BCL, n = 20), Hodgkin’s disease (n = 3), multiple myeloma (n = 9), natural killer/T-cell lymphoma (NK/TCL, n = 4), and TCL (n = 22).The median progression-free survival (PFS) was 27.4 months, while the median overall survival (OS) was 30.6 months.In univariate analysis, human leukocyte antigen (HLA) matching and complete remission status post-transplantation were associated with improved PFS and OS. However, only post-transplant response remained significant for both sur‑ vival outcomes in the multivariate analysis. Moreover, HLA matching was associated with a significantly improved PFS in patients with BCL and NK/TCL, but with better OS only in those with BCL. Complete remission after transplantation was associated with better PFS and OS in patients with BCL, NK/TCL, and TCL. Our results indicate that post-transplant response is an important prognostic indicator in allo-SCT for lymphoid malignancies and may guide clinical decisions and additional treatment.